Patents by Inventor Xiaoding Tan

Xiaoding Tan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION CONTAINING ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF
    Publication number: 20260174868
    Abstract: The present invention provides a preparation containing an anti-Nectin-4 Antibody-drug conjugate (ADC) and a use thereof. The preparation comprises an ADC, a buffering agent and an excipient. The anti-Nectin-4 ADC in the preparation exists stably, proteins do not aggregate after long-term storage, small molecule drugs are not prone to becoming detached, the osmotic pressure of the preparation is close to isotonic, and targeted therapy of Nectin-4 related diseases is facilitated.
    Type: Application
    Filed: October 27, 2023
    Publication date: June 25, 2026
    Inventors: Kun CHEN, Lingli WU, Rongyu JI, Fei MEI, Xiaoding TAN
  • CAMPTOTHECIN COMPOUND AND CONJUGATE THEREOF
    Publication number: 20250059201
    Abstract: Provided is a camptothecin compound, which is a compound represented by structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. An antibody-drug conjugate comprising the camptothecin compound is also provided.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 20, 2025
    Inventors: Wei ZHOU, Hui XU, Huikai ZHU, Zhenzhen WANG, Xiaoding TAN
  • METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN
    Publication number: 20240343678
    Abstract: A method for synthesizing 5,8-diamino-3,4-dihydro-2H-1-naphthalenone (Compound I), which method comprises: subjecting 2,5-diprotected aminophenylbutyric acid to the Friedel-Crafts reaction for ring closure, and then removing a protecting group on the amino group to obtain Compound I.
    Type: Application
    Filed: August 17, 2022
    Publication date: October 17, 2024
    Inventors: Hui XU, Wei ZHOU, Zhenzhen WANG, Xiaoding TAN
  • ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240226318
    Abstract: An antibody-drug conjugate targeting a poliovirus receptor-like molecule 4 (Nectin-4). The antibody-drug conjugate can be used for preparing a drug for treating Nectin-4-related diseases. The antibody-drug conjugate has strong targeting properties to Nectin-4 and a strong endocytosis effect via the target, and has an excellent tumor-killing effect.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 11, 2024
    Inventors: Wei ZHOU, Xiaoding TAN, Datao LIU
  • PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE
    Publication number: 20230372526
    Abstract: A preparation method for a bis-substituted bridging antibody-drug conjugate, comprising: hydrolyzing an antibody coupling product obtained by coupling an antibody to a compound as represented by formula I. Also provided is an antibody coupling product obtained by the preparation method.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 23, 2023
    Inventors: Wei ZHOU, Huikai ZHU, Zhenzhen WANG, Hui XU, Xiaoding TAN
  • PREPARATION PROCESS OF RECOMBINANT HUMAN P43 PROTEIN
    Publication number: 20100062488
    Abstract: A process for producing human p43 protein is provided, in which the p43 protein can be used as a drug for treating solid tumor.
    Type: Application
    Filed: January 17, 2008
    Publication date: March 11, 2010
    Applicant: Sine Pharmaceutical Laboratories
    Inventors: Datao Liu, Xiaoding Tan, Linda Hu, Yan Wang, Xi Zhu
  • Pharmaceutical Composition Comprising P43 Protein for the Treatment of Gastric Adenocarcinoma
    Publication number: 20090324573
    Abstract: A pharmaceutical composition for the treatment of gastric adenocarcinoma is provided, wherein the pharmaceutical composition comprises p43 protein and pharmaceutically acceptable carriers, and does not comprise paclitaxel. A use of p43 protein for the treatment of gastric adenocarcinoma is also provided.
    Type: Application
    Filed: May 26, 2009
    Publication date: December 31, 2009
    Inventors: Datao Liu, Xiaoding Tan, Xi Zhu, Yan Wang, Linda Hu